Rowe Scott, Liu Amy, Zagales Israel, Awan Muhammad, Santos Radleigh, McKenney Mark, Elkbuli Adel
From the Department of Surgery, Division of Trauma and Surgical Critical Care, Kendall Regional Medical Center, Miami, FL.
Department of Mathematics, Nova Southeastern University, Davie, FL.
Ann Surg Open. 2021 Nov 8;2(4):e105. doi: 10.1097/AS9.0000000000000105. eCollection 2021 Dec.
This systematic review and meta-analysis of randomized controlled trials (RCTs) aims to assess efficacy and safety of tranexamic acid (TXA) use in acute traumatic injuries.
PubMed and Cochrane libraries were searched for relevant RCTs published between January 2011 and January 3, 2021. Cohen's Q Test for heterogeneous effects was used to determine the appropriateness of fixed versus random effects models.
Twenty-two studies met inclusion criteria. Meta-analysis of relative risk of mortality between treatment and placebo groups in the in-hospital, and perioperative settings was not significant. However, the risk of mortality is significantly lower in the treatment versus placebo group when TXA was given as loading dose only. Ten of the 11 studies evaluating perioperative use of TXA included in systematic review found significantly lower blood loss in the treatment compared with placebo groups, but results of meta-analysis showed no significant difference. Results of meta-analysis indicate that the risk of venous thromboembolism (VTE) in the in-hospital treatment group is greater than that of the placebo. In subset analysis of studies using only a single loading dose, there were no significant differences in VTE.
Systematic review supports TXA benefits are most evident when given shortly after injury and meta-analysis supports TXA reduces mortality as a single loading dose. Systematic review supports perioperative use of TXA when large volume blood loss is anticipated. Meta-results showed no significant difference in risk of thromboembolism in single-dose TXA treatment compared with placebo. These findings suggest that TXA is safe and effective for control of traumatic bleeding.
本项对随机对照试验(RCT)的系统评价和荟萃分析旨在评估氨甲环酸(TXA)在急性创伤性损伤中的疗效和安全性。
检索PubMed和Cochrane图书馆,查找2011年1月至2021年1月3日期间发表的相关RCT。使用Cohen's Q检验评估异质性效应,以确定固定效应模型与随机效应模型的适用性。
22项研究符合纳入标准。对住院期间及围手术期治疗组与安慰剂组死亡率相对风险的荟萃分析无显著差异。然而,仅给予负荷剂量TXA时,治疗组的死亡率风险显著低于安慰剂组。系统评价纳入的11项评估TXA围手术期使用的研究中,有10项发现治疗组的失血显著低于安慰剂组,但荟萃分析结果显示无显著差异。荟萃分析结果表明,住院治疗组静脉血栓栓塞(VTE)的风险高于安慰剂组。在仅使用单一负荷剂量的研究亚组分析中,VTE无显著差异。
系统评价支持TXA在受伤后不久使用时益处最为明显,荟萃分析支持TXA作为单一负荷剂量可降低死亡率。系统评价支持在预计有大量失血时围手术期使用TXA。荟萃分析结果显示,单剂量TXA治疗与安慰剂相比,血栓栓塞风险无显著差异。这些发现表明,TXA对于控制创伤性出血是安全有效的。